Search results for "Disease management"

showing 10 items of 168 documents

Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience

2019

Many studies have reported a more favorable outcome in younger patients with Hodgkin lymphoma (HL). The aims of this study were to find an appropriate age cutoff able to identify low-risk children and to describe the natural history of 135 very young patients affected by classic HL (cHL). The best age cutoff was identified at 7 years of age. EFS (p = .0451) and PFS (p = .00921) were significantly better in the group of younger patients. The OS rate at 10 years was 97.0% in the younger group and 92.5% in the older one (p = .0448). However, age was not found to be an independent prognostic factor in multivariate analysis and the better prognosis in younger patients seems to be related to more…

MaleCancer Researchmedicine.medical_specialtyPrognostic factorMultivariate analysisAdolescent03 medical and health sciences0302 clinical medicineInternal medicineOutcome Assessment Health CaremedicineCutoffHumansPublic Health SurveillanceFavorable outcomeAge of OnsetChildchemotherapeutic approachesbusiness.industryAge FactorsDisease ManagementInfantHematologyPrognosisHodgkin DiseaseSurvival AnalysisNatural historypediatricOncologyItalyROC CurveSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisChild PreschoolLymphoma and Hodgkin diseaseHodgkin lymphomaDisease characteristicsFemalebusiness030215 immunology
researchProduct

Clinicopathological profile of gastrointestinal tuberculosis: a multinational ID-IRI study

2020

Data are relatively scarce on gastro-intestinal tuberculosis (GITB). Most studies are old and from single centers, or did not include immunosuppressed patients. Thus, we aimed to determine the clinical, radiological, and laboratory profiles of GITB. We included adults with proven GITB treated between 2000 and 2018. Patients were enrolled from 21 referral centers in 8 countries (Belgium, Egypt, France, Italy, Kazakhstan, Saudi Arabia, UK, and Turkey). One hundred four patients were included. Terminal ileum (n = 46, 44.2%), small intestines except terminal ileum (n = 36, 34.6%), colon (n = 29, 27.8%), stomach (n = 6, 5.7%), and perianal (one patient) were the sites of GITB. One-third of all p…

MaleCirrhosismedicine.medical_treatmentretrospective studylaparoscopyColonoscopymultimodal imagingComorbidityGastroenterologyprotionamide0302 clinical medicineLaparotomyAscitesamikacinMedicinebedaquilinePathologie maladies infectieusesintestine biopsyadultsteroidclinical trialGeneral MedicinerifabutinMicrobiologie et protistologie [entomologiephytoparasitolog.]priority journaldiabetes mellitushistopathologybiological productMicrobiology (medical)Microbiologie et protistologie [parasitologie hum. et anim.]medicine.medical_specialtyTuberculosis030106 microbiologymalignant neoplasmArticle03 medical and health scienceslaparotomyHuman immunodeficiency virus infectionmolecular diagnosisHumansTuberculosisGastro-intestinalhumanRetrospective Studiescolondisease predispositionmicrobiologyTuberculosis; Immune-suppression; Gastro-intestinal; Endoscopy;anusmedicine.diseasemajor clinical studymulticenter studyaminosalicylic acidcyclophosphamide0301 basic medicineBiopsyAntitubercular Agentsethambutolrifampicinterminal ileumcolonoscopyofloxacin030212 general & internal medicineLaparoscopyazathioprinemedicine.diagnostic_testIncidence (epidemiology)gastrointestinal tuberculosisDisease Managementchronic kidney failurecycloserineInfectious DiseasesfemaleTreatment OutcomeMolecular Diagnostic Techniquesdiagnostic testDisease Susceptibilitymedicine.symptommoxifloxacinSymptom AssessmentImmune-suppressionstomachisoniazidpyrazinamidestreptomycinliver cirrhosispatient referrallinezolidInternal medicineBiopsybusiness.industryEndoscopyMycobacterium tuberculosishuman tissueclinical featureTreatmentTuberculosis Gastrointestinaltuberculostatic agentbusinessMicrobiologie et protistologie [bacteriol.virolog.mycolog.]
researchProduct

Motives for and barriers to physical activity among older adults with mobility limitations

2007

The purpose of this study was to investigate what older adults with severe, moderate, or no mobility limitation consider motives for and barriers to engaging in physical exercise. Community-dwelling adults (N = 645) age 75–81 years completed a questionnaire about their motives for and barriers to physical exercise and answered interview questions on mobility limitation. Those with severely limited mobility more often reported poor health, fear and negative experiences, lack of company, and an unsuitable environment as barriers to exercise than did those with no mobility limitation. They also accentuated disease management as a motive for exercise, whereas those with no or moderate mobility …

MaleGerontologyAgingActivities of daily livingFrail ElderlyPhysical activityPhysical Therapy Sports Therapy and RehabilitationPhysical exerciseMotor ActivityInterviews as TopicActivities of Daily LivingHumansMobility LimitationDisease management (health)Exercise physiologyExerciseGeriatric AssessmentAgedAged 80 and overRehabilitationAge FactorsHealth SurveysHealth promotionMobility LimitationFemaleSupport systemGeriatrics and GerontologyPsychologyGerontologySocial psychology
researchProduct

An Expert Opinion From the European Society of Hypertension–European Union Geriatric Medicine Society Working Group on the Management of Hypertension…

2016

Two years after the publication of the 2013 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC),1 the ESH and the European Union Geriatric Medicine Society have created a common working group to examine the management of hypertensive subjects aged >80 years. The general term hypertension in the elderly is not sufficiently accurate because it mixes younger old patients (60–70 years) with the oldest old. Our group believes that the management of hypertension in individuals aged ≥80 years should be specifically addressed. Although arbitrary, this cutoff value identifies a population that is expanding …

MaleGerontologyBLOOD-PRESSUREL-ARGININE TRANSPORTFAT-FED RABBITS030204 cardiovascular system & hematologySeverity of Illness IndexSYMPATHETIC-NERVE ACTIVITY0302 clinical medicine80 and overPerindopril030212 general & internal medicineDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUSMETABOLIC SYNDROMEmedia_commonAged 80 and overGeriatricseducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyIndapamideDisease ManagementPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthAntihypertensive AgentTreatment OutcomeHypertensionPractice Guidelines as TopicFemaleSurvival AnalysiHumanmedicine.drugANGIOTENSIN-CONVERTING ENZYMEmedicine.medical_specialtyPrognosiFrail ElderlyeducationPopulationRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMedicalInternal MedicinemedicineHumansmedia_common.cataloged_instanceEuropean UnionNITRIC-OXIDE SYNTHASEEuropean unioneducationREDUCES OXIDATIVE STRESSExpert TestimonyGeriatric AssessmentAntihypertensive AgentsAgedAged; Aged 80 and over; Antihypertensive Agents; Blood Pressure Determination; Disease Management; European Union; Expert Testimony; Female; Frail Elderly; Geriatric Assessment; Geriatrics; Humans; Hypertension; Male; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Survival Analysis; Treatment Outcome; Practice Guidelines as Topic; Internal Medicinebusiness.industryBlood Pressure DeterminationSurvival AnalysisBlood pressureOBESITY-INDUCED HYPERTENSIONGeriatrics3121 General medicine internal medicine and other clinical medicineENDOTHELIAL DYSFUNCTIONLife expectancySocietiesbusinessGeriatric[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHypertension
researchProduct

2017 WSES guidelines for the management of iatrogenic colonoscopy perforation

2017

Abstract Iatrogenic colonoscopy perforation (ICP) is a severe complication that can occur during both diagnostic and therapeutic procedures. Although 45–60% of ICPs are diagnosed by the endoscopist while performing the colonoscopy, many ICPs are not immediately recognized but are instead suspected on the basis of clinical signs and symptoms that occur after the endoscopic procedure. There are three main therapeutic options for ICPs: endoscopic repair, conservative therapy, and surgery. The therapeutic approach must vary based on the setting of the diagnosis (intra- or post-colonoscopy), the type of ICP, the characteristics and general status of the patient, the operator’s level of experienc…

MaleIatrogenic DiseaseColonoscopyReviewIatrogenic colonoscopy perforation0302 clinical medicine80 and overOpen abdomenAged 80 and overintegumentary systemmedicine.diagnostic_testmusculoskeletal neural and ocular physiologylcsh:Medical emergencies. Critical care. Intensive care. First aidDisease ManagementIatrogenic colonoscopy perforation Colonoscopy Gastrointestinal endoscopy Emergency surgery Laparoscopy Antibiotic therapy Intra-abdominal infection Open abdomenColonoscopyMiddle Agedhumanities030220 oncology & carcinogenesisEmergency surgeryEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.medical_specialtyColonPerforation (oil well)lcsh:SurgeryGuidelines as TopicSigns and symptomsGeneral status03 medical and health sciencesTherapeutic approachIntra-abdominal infectionEmergency surgerymedicineHumansGastrointestinal endoscopyIntensive care medicineAgedbusiness.industrylcsh:RD1-811lcsh:RC86-88.9Antibiotic therapyEndoscopic Procedurenervous system diseasesSettore MED/18 - Chirurgia GeneraleIntestinal PerforationAntibiotic therapy; Colonoscopy; Emergency surgery; Gastrointestinal endoscopy; Iatrogenic colonoscopy perforation; Intra-abdominal infection; Laparoscopy; Open abdomen; Aged; Aged 80 and over; Colon; Colonoscopy; Disease Management; Female; Humans; Intestinal Perforation; Male; Middle Aged; Guidelines as Topic; Iatrogenic DiseaseAntibiotic therapy; Colonoscopy; Emergency surgery; Gastrointestinal endoscopy; Iatrogenic colonoscopy perforation; Intra-abdominal infection; Laparoscopy; Open abdomen;LaparoscopySurgerySurgical devicebusiness
researchProduct

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

2019

Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1−G2 NET. Methods: A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and grade of side effects and the rate of dose reduction/treatment discontinuation. Results: Among 1182 patients with neuroendocrine neoplasia included in the ELIOS database, 131 G1–G2 ga…

MaleOncologymedicine.medical_specialtyHigh-dose somatostatin analogs; neuroendocrine tumors; PRRT; sequence of treatments; somatostatin analogues; targeted therapyLung NeoplasmsDatabases FactualSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic AgentsHigh-dose somatostatin analogNeuroendocrine tumorsOctreotideSomatostatin analogueTargeted therapySettore MED/13 - EndocrinologiaTargeted therapyEndocrinologyNeuroendocrine tumorStomach NeoplasmsInternal medicineDiabetes mellitusIntestinal NeoplasmsSequence of treatmentmedicineHumansEverolimusRetrospective StudiesChemotherapyEverolimusbusiness.industryDisease ManagementMiddle Agedmedicine.diseaseDiscontinuationPancreatic NeoplasmsNeuroendocrine TumorsRadionuclide therapyFemaleObservational studyPRRTSomatostatinbusinessmedicine.drug
researchProduct

Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study

2020

The management regarding metastatic colorectal cancer throughout Europe is not well known.To draw a European comparison of the management and prognosis of metastatic colorectal cancers.Factors associated with chemotherapy administration were identified through logistic regressions. Net survival was estimated and crude probabilities of death related to cancer and other causes using a flexible cumulative hazard model.Among the 13 227 patients with colorectal cancer diagnosed between 2010 and 2013 in cancer registries from 10 European countries, 3140 were metastatic. 62% of metastatic patients received chemotherapy. Compared to Spain, the related adjusted odds ratios ranged from 0.7 to 4.0 (P0…

MaleOncologymedicine.medical_specialtySurvivalColorectal cancerPopulationAntineoplastic AgentsLogistic regressionMetastasisMetastasis03 medical and health sciences0302 clinical medicineInternal medicineHealth caremedicineHumansRegistriesNeoplasm MetastasisDisease management (health)educationAgedRetrospective StudiesAged 80 and overeducation.field_of_studyHepatologybusiness.industryGastroenterologyDisease ManagementCancerOdds ratioMiddle Agedmedicine.diseaseColorectal cancerEurope030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologyColorectal NeoplasmsbusinessDigestive and Liver Disease
researchProduct

Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients

2016

International audience; Anemia management, based on erythropoiesis stimulating agents (ESA) and iron supplementation, has become an increasingly challenging problem in hemodialysis patients. Maintaining hemodialysis patients within narrow hemoglobin targets, preventing cycling outside target, and reducing ESA dosing to prevent adverse outcomes requires considerable attention from caregivers. Anticipation of the long-term response (i.e. at 3 months) to the ESA/iron therapy would be of fundamental importance for planning a successful treatment strategy. To this end, we developed a predictive model designed to support decision-making regarding anemia management in hemodialysis (HD) patients tr…

MalePediatricsBlood transfusionDarbepoetin alfaPhysiologymedicine.medical_treatment030232 urology & nephrologylcsh:Medicine030204 cardiovascular system & hematologyFerric CompoundsBiochemistryGlucaric AcidHemoglobinsMathematical and Statistical Techniques0302 clinical medicineMedicine and Health SciencesDarbepoetin alfaErythropoiesislcsh:ScienceFerric Oxide SaccharatedMultidisciplinaryPharmaceuticsDisease ManagementAnemia[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyMiddle Aged3. Good healthNephrologyInjections IntravenousPhysical SciencesFemaleHemodialysisStatistics (Mathematics)Research Articlemedicine.drugComputer and Information Sciencesmedicine.medical_specialtyAnemiaResearch and Analysis Methods03 medical and health sciencesDose Prediction MethodsRenal DialysisArtificial IntelligenceMedical DialysismedicineHumansHemoglobinDosingStatistical MethodsIron Deficiency AnemiaIntensive care medicineArtificial Neural NetworksAgedRetrospective StudiesComputational NeuroscienceModels Statisticalbusiness.industrylcsh:RBiology and Life SciencesComputational BiologyProteinsRetrospective cohort studymedicine.diseaseIron-deficiency anemiaHematinicsKidney Failure ChronicCognitive Sciencelcsh:QNeural Networks ComputerHemoglobinPhysiological ProcessesbusinessMathematicsNeuroscienceForecasting
researchProduct

Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study

2017

The natural history and its modulation by treatments administered for immune thrombocytopenia (ITP) in the clinical practice remains unknown. In addition, little information is available on the characteristics and management of ITP in Spain. We conducted an observational, multicenter, registry in 70 Hematology Services from Spain between 2009 and 2011, which included children from 2 months of age and adults with primary ITP or another ITP diagnosed within the last 6 months (platelet count [PC]  484 patients were included (median [Q1, Q3] age 52 [29,74] years, 87.6% adults), 56% women, 10.5% with secondary ITP. Median (Q1, Q3) PC at diagnosis was 12 × 109/l (4, 32); 72% of patients had bleed…

MalePediatricsRegistry studyComorbidity030204 cardiovascular system & hematologycorticosteroids0302 clinical medicineAdrenal Cortex Hormonesimmune system diseaseshemic and lymphatic diseasesRegistriesChildresponseHematologyDisease ManagementImmunoglobulins IntravenousHematologyMiddle AgedClinical PracticeNatural historyPhenotypeTreatment OutcomeIntravenous ImmunoglobulinsChild PreschoolFemaleAlgorithmsAdultmedicine.medical_specialtyAdolescentHemorrhageintravenous immunoglobulinsYoung Adult03 medical and health sciencesImmune systemInternal medicinemedicineHumansAgedPurpura Thrombocytopenic IdiopathicPlatelet Countbusiness.industryInfantImmune thrombocytopeniaImmune thrombocytopeniaSpainObservational studybusinessBiomarkers030215 immunologyHematology
researchProduct

Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and manag…

2018

Abstract The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt diagnosis and appropriate treatment on the basis of different specialists’ contributions in the field. A set of 40 recommendations is provided, divided in two parts: the first describes the definition of KD, its epidemiology, etiopathogenetic hints, presentation, clinical course and general management, including treatment of the acute phase, through specific 23 recommendations. Their application is aimed at improving the rate of treatment with intravenous immunoglobulin and the overall potential development of coronary artery abnormalities in KD. Guidelines, however, should…

MalePediatricsReviewPediatricsSeverity of Illness Index0302 clinical medicineRetrospective StudieEpidemiology030212 general & internal medicineDisease management (health)Coronary artery abnormalitieChildrenSocieties MedicalRandomized Controlled Trials as TopicPediatriclcsh:RJ1-570Disease ManagementImmunoglobulins IntravenousGeneral MedicinePrognosisSettore MED/38Treatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyMeta-analysisAcute DiseasePractice Guidelines as TopicDisease ProgressionFemaleCoronary artery abnormalitiesAspirin; Children; Coronary artery abnormalities; Intravenous immunoglobulin; Kawasaki disease;Humanmedicine.medical_specialtyPrognosiMucocutaneous Lymph Node SyndromeRisk Assessment03 medical and health sciences030225 pediatricsSeverity of illnessmedicineHumansRisk factorIntravenous immunoglobulinRetrospective Studiesaspirin; children; coronary artery abnormalities; intravenous immunoglobulin; Kawasaki disease; pediatrics perinatology and child healthAspirinKawasaki diseasebusiness.industrylcsh:PediatricsRetrospective cohort studymedicine.diseaseImmunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseDifferential diagnosisbusiness
researchProduct